Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug774 | COVID-19 patients Wiki | 0.71 |
| drug953 | Cognitive Behavioral Therapy Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001416 | Back Pain NIH | 0.71 |
| D017116 | Low Back Pain NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0003418 | Back pain HPO | 0.71 |
| HP:0003419 | Low back pain HPO | 0.71 |
Navigate: Correlations HPO
There is one clinical trial.
Chronic low back pain (CLBP) has no known effective treatment. While often treated with long-term opioid therapy, opioids do not work well for many patients and can cause serious side effects, including addiction, poorer mental health, and overdose death. Even when paired with a standard-of-care cognitive behavioral therapy (CBT), results are limited. Patients, families and clinicians are very interested in using alternative treatments for CLBP, especially complementary and integrative treatments such as mindfulness meditation (MM). MM helps train the mind to bring non-judgmental and accepting attention to present-moment experiences such as pain. MM offers an active and safe self-care approach to chronic pain that contrasts with the passive and potentially harmful nature of opioid treatment, and may prove more effective than CBT in helping improve health and well-being, and reduce reliance on opioids in adults with opioid-treated CLBP. Although this hypothesis is supported by early research, including a pilot study by the Principal Investigator, evidence on MM's effectiveness in this population is inconclusive, presenting a critical knowledge gap. With input from patients, family members, and clinicians, the Investigators have designed a study to address this gap and propose a clinical trial that will compare the effectiveness of MM to standard-of-care CBT in opioid-treated CLBP. Based on the existing research, it is hypothesized that MM training will lead to a larger reduction in pain intensity, increase in physical function, improvement in quality of life, and decrease in daily opioid dose, as compared to CBT training, with benefits of MM especially notable in adults with worse mood, anxiety or unhealthy opioid-use behaviors who often experience more severe symptoms of CLBP and less improvement in response to existing therapies. To test these hypotheses, 766 adults with opioid-treated CLBP will be randomly assigned into one of two 8-week treatment groups: MM (383 participants) that will receive the MM training or CBT (383 participants) that will receive the CBT training. Due to the COVID-19 pandemic-related restrictions, the study protocol was modified in October 2020 so that the study can be completed virtually. The effectiveness of MM versus CBT will be assessed over a 12-month period with patient-reported measures, recommended by experts and endorsed by our stakeholder partners, including patients with opioid-treated CLBP, their families and clinicians.
Description: 4 pain severity items from the Brief Pain Inventory
Measure: Pain Intensity Time: Baseline to 12 monthsDescription: 10-item Oswestry Disability Index
Measure: Physical Function Time: Baseline to 12 monthsDescription: 12-item Short Form-12
Measure: Quality of Life Time: Baseline to 12 monthsDescription: Timeline Followback Method (morphine-equivalent dose [mg/day] over the prior 14 days)
Measure: Daily Opioid Dose Time: Baseline to 12 monthsDescription: 14-item Hospital Anxiety and Depression Scale
Measure: Depression Symptom Severity Time: Baseline to 12 monthsDescription: 14-item Hospital Anxiety and Depression Scale
Measure: Anxiety Symptom Severity Time: Baseline to 12 monthsDescription: 17-item Current Opioid Misuse Measure
Measure: Opioid Use Behaviors Time: Baseline to 12 monthsDescription: 8-item Opioid Compliance Checklist
Measure: Opioid Medication Compliance Time: Baseline to 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports